One of the main limitations of the highly used cancer imaging technique, PET-CT, is its inability to distinguish between cancerous lesions and post treatment inflammatory conditions. The reason for this lack of specificity is that [18F]FDG-PET is based on increased glucose metabolic activity, which characterizes both cancerous tissues and inflammatory cells. To overcome this limitation, we developed a nanoparticle-based approach, utilizing glucose-functionalized gold nanoparticles (GF-GNPs) as a metabolically targeted CT contrast agent. Our approach demonstrates specific tumor targeting and has successfully distinguished between cancer and inflammatory processes in a combined tumor-inflammation mouse model, due to dissimilarities in angiogenesis occurring under different pathologic conditions. This study provides a set of capabilities in cancer detection, staging and follow-up, and can be applicable to a wide range of cancers that exhibit high metabolic activity.
|Number of pages||9|
|State||Published - 22 Mar 2016|
Bibliographical noteFunding Information:
This work was partially supported by the Research and Development Chief Scientist Kamin grant (49544), by the Israel Cancer Research Fund (ICRF), by the Israel Science Foundation grant (749/14), and by the doctoral scholarship for applicable and scientific engineering research, granted to Tamar Dreifuss and Oshra Betzer by the Ministry of Science, Technology & Space, Israel.
© 2016 American Chemical Society.
- gold nanoparticles
- metabolic-based imaging